Company Overview
Company Type: Private Company
Website: www.soricimed.com
Number of Employees: -
Year Founded: 2005
Total Amount Raised (CAD mm)†: 0.34
Total Rounds of Funding**:3
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Soricimed Biopharma Inc. operates as a drug and diagnostic development company. It develops a cancer management program that is focused on an ovarian cancer therapeutic and a companion early diagnostic. Its products pipeline includes SOR-C13 and SOR-C27 for ovarian, breast, and prostate cancers; SOR-N54 for pain; and SOR-D01 and SOR-D02 for ovarian, breast, and prostate cancers. Soricimed Biopharma Inc. was formerly known as BioProspecting NB Inc. and changed its name to Soricimed Biopharma Inc. in 2010. The company was founded in 2005 and is based in Moncton, Canada. It has a lab in Sackville, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Bruce, Robert 
Chief Executive Officer
Gunn, Paul 
President & Director
Stewart, John M.
Founder, Chief Scientific Officer, Director & Chairman of Scientific Advisory Committee
Michalargias, Photios 
Chief Financial Officer
Ilenchuk, T. Toney
Chief Development Officer and Member of Scientific Advisory Committee

Key Board Members
Name
Title
Embro-Pantalony, Vaughn C.
Chairman of Board
Gunn, Paul 
President & Director
Stewart, John M.
Founder, Chief Scientific Officer, Director & Chairman of Scientific Advisory Committee
Ilenchuk, T. Toney
Chief Development Officer and Member of Scientific Advisory Committee
Belliveau, Camille
Director
Berchtold, Nicole
Member of Scientific Advisory Committee
Fu, Siqing 
Member of Scientific Advisory Board
Gribkoff, Valentin K.
Member of Scientific Advisory Committee
Hicks, Susan 
Director
Nigam, Rita
Member of Scientific Advisory Committee
Ouellette, Rodney 
Member of Scientific Advisory Board
Reiman, Anthony J.
Member of Scientific Advisory Committee


Primary Industry Classification
Biotechnology


Primary Office Location
18 Botsford Street Suite 200 | Moncton, NB | E1C 4W7 | Canada
Phone: 506-872-2181   Fax: 506-856-0414

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
New Brunswick Innovation Foundation
-
Minority
-
-

Prior Investors
New Brunswick Innovation Foundation, Investment Arm


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jul-13-2022
Jul-13-2022
Private Placement
Target
Soricimed Biopharma Inc.


0.15
Jul-23-2021
-
Private Placement
Target
Soricimed Biopharma Inc.


-
Sep-30-2011
-
Private Placement
Target
Soricimed Biopharma Inc.


0.11
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Dec-13-2022
Executive/Board Changes - Other
Soricimed Appoints Dr. Siqing Fu to Its Scientific Advisory Board
Jul-13-2022
Private Placements
Soricimed Biopharma Inc. announced that it has received CAD 0.2 million in funding
Jun-02-2022
Executive/Board Changes - Other
Soricimed Biopharma Inc. Appoints Rodney Ouellette to Its Scientific Advisory Board
May-16-2022
Executive Changes - CFO
Soricimed Biopharma Inc. Appoints Frank Michalargias as Chief Financial Officer
Nov-09-2021
Strategic Alliances
Mount Allison University to Collaborate with Soricimed Biopharma Inc. on Novel Biopesticide Solution


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 18, 2023 03:44 AM
Soricimed Biopharma Inc.
Soricimed Biopharma Inc
Reports
78
GlobalData

Sep 15, 2023 08:56 AM
Soricimed Biopharma Inc.
Soricimed Biopharma Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
37
GlobalData

Jul 27, 2023 06:58 AM
Soricimed Biopharma Inc.
Soricimed Biopharma Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
24
GlobalData

Jun 28, 2023 04:11 AM
Soricimed Biopharma Inc.
Soricimed Biopharma Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
24
GlobalData

Jun 15, 2023 02:10 AM
Soricimed Biopharma Inc.
Soricimed Biopharma Inc
Reports
78
GlobalData

Jun 09, 2023 05:29 AM
Soricimed Biopharma Inc.
Soricimed Biopharma Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
37
GlobalData

Mar 16, 2023 03:40 AM
Soricimed Biopharma Inc.
Soricimed Biopharma Inc
Reports
79
GlobalData

Mar 10, 2023 03:40 AM
Soricimed Biopharma Inc.
Soricimed Biopharma Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
39
GlobalData

Feb 10, 2023 05:21 AM
Soricimed Biopharma Inc.
Soricimed Biopharma Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
24
GlobalData

Dec 14, 2022 02:33 AM
Soricimed Biopharma Inc.
Soricimed Biopharma Inc
Reports
78


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
SOR-C13 (Future), SOR-C27 (Future)

Key Board Members Details
Name
Title
Phone
Fax
Email
Embro-Pantalony, Vaughn C.
Chairman of Board
506-872-2181
506-856-0414
vaughn.embro-pantalony@microbix.com
Gunn, Paul 
President & Director
506-856-0400
506-856-0414
pgunn@soricimed.com
Stewart, John M.
Founder, Chief Scientific Officer, Director & Chairman of Scientific Advisory Committee
506-872-2181
506-856-0414

Ilenchuk, T. Toney
Chief Development Officer and Member of Scientific Advisory Committee
506-872-2181
506-856-0414
-
Belliveau, Camille
Director
506-872-2181
506-856-0414
-
Berchtold, Nicole
Member of Scientific Advisory Committee
506-872-2181
506-856-0414
-
Fu, Siqing 
Member of Scientific Advisory Board
506-872-2181
506-856-0414

Gribkoff, Valentin K.
Member of Scientific Advisory Committee
506-872-2181
506-856-0414
-
Hicks, Susan 
Director
506-872-2181
506-856-0414
-
Nigam, Rita
Member of Scientific Advisory Committee
506-872-2181
506-856-0414
-
Ouellette, Rodney 
Member of Scientific Advisory Board
506-872-2181
506-856-0414

Reiman, Anthony J.
Member of Scientific Advisory Committee
506-872-2181
506-856-0414
-
* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Bruce, Robert 
Chief Executive Officer
506-872-2181
506-856-0414

Gunn, Paul 
President & Director
506-856-0400
506-856-0414
pgunn@soricimed.com
Stewart, John M.
Founder, Chief Scientific Officer, Director & Chairman of Scientific Advisory Committee
506-872-2181
506-856-0414

Michalargias, Photios 
Chief Financial Officer
506-872-2181
506-856-0414

Ilenchuk, T. Toney
Chief Development Officer and Member of Scientific Advisory Committee
506-872-2181
506-856-0414
-
* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
